SUMMIT, N.J.--(BUSINESS WIRE)--
2007 Second Quarter Financial Results Year-Over-Year:
* Total Revenue Increased 76 Percent To $348 Million
* Product Sales Increased 81 Percent To $319 Million
* REVLIMID® Net Product Sales Increased 187 Percent To $181 Million
* THALOMID® Net Product Sales Totaled $118 Million
* Adjusted Operating Income Increased 143 Percent To $130 Million
* Adjusted Net Income Increased 160 Percent To $110 Million
* Adjusted Earnings Per Share Increased 136 Percent To $0.26 Per Diluted Share
